Minerva Neurosciences Change in Accounts Payable 2013-2025 | NERV

Minerva Neurosciences change in accounts payable from 2013 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

Minerva Neurosciences Change in Accounts Payable 2013-2025 | NERV

Minerva Neurosciences change in accounts payable from 2013 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$95B
Zoetis (ZTS)$66.3B
Takeda Pharmaceutical (TAK)$46.8B
Daiichi Sankyo, - (DSNKY)$41.7B
Summit Therapeutics (SMMT)$18.2B
Sandoz Group AG (SDZNY)$17.7B
Merck (MKKGY)$17.2B
Astellas Pharma (ALPMY)$16.9B
Shionogi (SGIOY)$14.1B
United Therapeutics (UTHR)$12.8B
Neurocrine Biosciences (NBIX)$10B
IPSEN (IPSEY)$8.6B
Orion OYJ (ORINY)$8B
Madrigal Pharmaceuticals (MDGL)$6.7B
Stevanato Group S.p.A (STVN)$6.6B
Corcept Therapeutics (CORT)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$5.8B
Ono Pharmaceutical (OPHLF)$5.5B
Grifols, S.A (GRFS)$4.9B
Ionis Pharmaceuticals (IONS)$4.5B
Soleno Therapeutics (SLNO)$3.2B
Crinetics Pharmaceuticals (CRNX)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.3B
Recursion Pharmaceuticals (RXRX)$2.2B
Hypermarcas (HYPMY)$2.1B
NewAmsterdam Pharma (NAMS)$1.8B
Centessa Pharmaceuticals (CNTA)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.5B
Guardian Pharmacy Services (GRDN)$1.5B